Impact AI Managing Eye Diseases with Carlos Ciller from RetinAI
Using AI for medical data analysis for eye diseases has the potential to significantly improve diagnosis, treatment, and patient care in ophthalmology. In this episode, I sit down with Carlos Ciller, Co-Founder and CEO of RetinAI, to discuss the impact of AI in the field of healthcare, specifically in the context of RetinAI, a company focused on using AI for medical data analysis for eye diseases. In our conversation, we unpack the world of mission-driven impact in healthcare as Carlos shares his journey from engineer to innovator.
Uncover how RetinAI's flagship product, "Discovery," is revolutionizing healthcare with AI-powered medical image and data management. Explore the diverse data sources and AI models used, the importance of model robustness, and the influence of regulatory processes. Carlos also discusses the benefits of publishing research and the potential of generative AI, and he offers valuable advice for AI startup leaders. Finally, learn about RetinAI's vision for the future, including its expansion into new therapeutic areas and the pursuit of digital precision medicine. Tune in to uncover the incredible impact of AI in healthcare and RetinAI's pivotal role in this transformation with Carlos Ciller!
Key Points:
- Carlos’ professional background and his passion for meaningful healthcare solutions.
- RetinAI’s mission and the range of healthcare products it provides.
- The types of data and AI models that RetinAI leverages.
- Challenges of dealing with diverse data sources, devices, and patient characteristics.
- Ensuring model performance and accuracy in the long term.
- Frozen with fixed weights versus continuous learning models.
- Discover how regulatory processes influence AI development.
- He explains the benefits of publishing research for the development process.
- Explore the potential of generative AI in healthcare.
- Learn the importance of ‘wrapping’ the technology with the right product
- Focusing on the customer, starting small, and letting the market define the product.
- His vision for RetinAI's impact in the next three to five years.
Quotes:
“[RetinAI is] a software company. We are software that is enabling the right decisions sooner in healthcare, and that, of course, goes a long way.” — Carlos Ciller
“One of the secret sauces of the company is that around 40% to 50% of the team has actually a very strong academic training, specifically in the ophthalmology space.” — Carlos Ciller
“Quality is the most important aspect. If you work on quality [data], you will create stronger models.” — Carlos Ciller
“I think the regulations that we have today, and some of the guidelines and support material provided by regulatory agencies and some of the leaders in academic space are precisely [there] to help you not commit the same mistakes that others committed in the past.” — Carlos Ciller
“I think that it's important to share your research, and you can still make a good company out of sharing your own research, and letting others build on top of what you are building.” — Carlos Ciller
Links:
Resources for Computer Vision Teams:
LinkedIn – Connect with Heather.
Computer Vision Insights Newsletter – A biweekly newsletter to help bring the latest machine learning and computer vision research to applications in people and planetary health.
Computer Vision Strategy Session – Not sure how to advance your computer vision project? Get unstuck with a clear set of next steps. Schedule a 1 hour strategy session now to advance your project.
Computer Vision Advisory Services – Monthly advisory services to help you strategically plan your CV/ML capabilities, reduce the trial-and-error of model development, and get to market faster.